|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MFN1 |
Gene summary for MFN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MFN1 | Gene ID | 55669 |
| Gene name | mitofusin 1 | |
| Gene Alias | hfzo1 | |
| Cytomap | 3q26.33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A0C4DFN1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55669 | MFN1 | CA_HPV_2 | Human | Cervix | CC | 2.35e-08 | 3.93e-01 | 0.0391 |
| 55669 | MFN1 | CCI_1 | Human | Cervix | CC | 2.43e-02 | 4.84e-01 | 0.528 |
| 55669 | MFN1 | CCI_2 | Human | Cervix | CC | 3.59e-09 | 9.62e-01 | 0.5249 |
| 55669 | MFN1 | CCI_3 | Human | Cervix | CC | 1.28e-03 | 5.47e-01 | 0.516 |
| 55669 | MFN1 | LZE4T | Human | Esophagus | ESCC | 2.44e-11 | 3.50e-01 | 0.0811 |
| 55669 | MFN1 | LZE5T | Human | Esophagus | ESCC | 2.88e-05 | 5.29e-01 | 0.0514 |
| 55669 | MFN1 | LZE7T | Human | Esophagus | ESCC | 2.13e-03 | 2.78e-01 | 0.0667 |
| 55669 | MFN1 | LZE8T | Human | Esophagus | ESCC | 5.24e-07 | 2.81e-01 | 0.067 |
| 55669 | MFN1 | LZE20T | Human | Esophagus | ESCC | 6.00e-06 | 1.30e-01 | 0.0662 |
| 55669 | MFN1 | LZE24T | Human | Esophagus | ESCC | 5.74e-16 | 4.89e-01 | 0.0596 |
| 55669 | MFN1 | LZE6T | Human | Esophagus | ESCC | 6.87e-05 | 2.84e-01 | 0.0845 |
| 55669 | MFN1 | P1T-E | Human | Esophagus | ESCC | 2.81e-07 | 4.07e-01 | 0.0875 |
| 55669 | MFN1 | P2T-E | Human | Esophagus | ESCC | 1.46e-37 | 7.74e-01 | 0.1177 |
| 55669 | MFN1 | P4T-E | Human | Esophagus | ESCC | 9.21e-20 | 4.98e-01 | 0.1323 |
| 55669 | MFN1 | P5T-E | Human | Esophagus | ESCC | 1.15e-27 | 6.04e-01 | 0.1327 |
| 55669 | MFN1 | P8T-E | Human | Esophagus | ESCC | 1.50e-16 | 3.20e-01 | 0.0889 |
| 55669 | MFN1 | P9T-E | Human | Esophagus | ESCC | 1.13e-05 | 2.34e-01 | 0.1131 |
| 55669 | MFN1 | P10T-E | Human | Esophagus | ESCC | 5.65e-23 | 4.84e-01 | 0.116 |
| 55669 | MFN1 | P11T-E | Human | Esophagus | ESCC | 4.17e-04 | 3.46e-01 | 0.1426 |
| 55669 | MFN1 | P12T-E | Human | Esophagus | ESCC | 1.42e-25 | 5.91e-01 | 0.1122 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00091449 | Cervix | CC | purine nucleoside triphosphate metabolic process | 29/2311 | 88/18723 | 3.62e-07 | 1.45e-05 | 29 |
| GO:00092058 | Cervix | CC | purine ribonucleoside triphosphate metabolic process | 27/2311 | 82/18723 | 9.24e-07 | 3.25e-05 | 27 |
| GO:00091998 | Cervix | CC | ribonucleoside triphosphate metabolic process | 28/2311 | 89/18723 | 1.65e-06 | 5.44e-05 | 28 |
| GO:00091419 | Cervix | CC | nucleoside triphosphate metabolic process | 31/2311 | 112/18723 | 9.38e-06 | 2.11e-04 | 31 |
| GO:00070067 | Cervix | CC | mitochondrial membrane organization | 28/2311 | 116/18723 | 3.28e-04 | 3.47e-03 | 28 |
| GO:00196939 | Cervix | CC | ribose phosphate metabolic process | 72/2311 | 396/18723 | 4.49e-04 | 4.48e-03 | 72 |
| GO:00092599 | Cervix | CC | ribonucleotide metabolic process | 70/2311 | 385/18723 | 5.35e-04 | 5.18e-03 | 70 |
| GO:000915010 | Cervix | CC | purine ribonucleotide metabolic process | 66/2311 | 368/18723 | 1.09e-03 | 9.07e-03 | 66 |
| GO:000616310 | Cervix | CC | purine nucleotide metabolic process | 67/2311 | 396/18723 | 4.41e-03 | 2.69e-02 | 67 |
| GO:007252110 | Cervix | CC | purine-containing compound metabolic process | 69/2311 | 416/18723 | 6.27e-03 | 3.54e-02 | 69 |
| GO:00516461 | Cervix | CC | mitochondrion localization | 13/2311 | 50/18723 | 6.42e-03 | 3.58e-02 | 13 |
| GO:000911710 | Cervix | CC | nucleotide metabolic process | 79/2311 | 489/18723 | 7.16e-03 | 3.85e-02 | 79 |
| GO:000700619 | Esophagus | ESCC | mitochondrial membrane organization | 93/8552 | 116/18723 | 2.16e-14 | 1.11e-12 | 93 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009141111 | Esophagus | ESCC | nucleoside triphosphate metabolic process | 78/8552 | 112/18723 | 2.36e-07 | 3.59e-06 | 78 |
| GO:00482844 | Esophagus | ESCC | organelle fusion | 94/8552 | 141/18723 | 3.72e-07 | 5.16e-06 | 94 |
| GO:0009259111 | Esophagus | ESCC | ribonucleotide metabolic process | 224/8552 | 385/18723 | 4.41e-07 | 6.00e-06 | 224 |
| GO:0072521111 | Esophagus | ESCC | purine-containing compound metabolic process | 238/8552 | 416/18723 | 1.20e-06 | 1.49e-05 | 238 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| hsa0413718 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
| hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| hsa0413719 | Cervix | CC | Mitophagy - animal | 22/1267 | 72/8465 | 5.77e-04 | 2.75e-03 | 1.63e-03 | 22 |
| hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
| hsa05012211 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
| hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa04137210 | Esophagus | ESCC | Mitophagy - animal | 54/4205 | 72/8465 | 9.33e-06 | 4.96e-05 | 2.54e-05 | 54 |
| hsa0462122 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
| hsa05012310 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
| hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
| hsa0413738 | Esophagus | ESCC | Mitophagy - animal | 54/4205 | 72/8465 | 9.33e-06 | 4.96e-05 | 2.54e-05 | 54 |
| hsa0462132 | Esophagus | ESCC | NOD-like receptor signaling pathway | 116/4205 | 186/8465 | 2.90e-04 | 1.03e-03 | 5.30e-04 | 116 |
| hsa0501230 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
| hsa0502228 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
| hsa0413728 | Oral cavity | OSCC | Mitophagy - animal | 58/3704 | 72/8465 | 1.48e-10 | 2.07e-09 | 1.05e-09 | 58 |
| hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MFN1 | SNV | Missense_Mutation | c.329N>G | p.Asn110Ser | p.N110S | protein_coding | deleterious(0) | benign(0.077) | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD | ||
| MFN1 | SNV | Missense_Mutation | novel | c.1969A>G | p.Ile657Val | p.I657V | protein_coding | tolerated(0.18) | benign(0.045) | TCGA-R5-A7ZI-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| MFN1 | SNV | Missense_Mutation | novel | c.1634T>G | p.Leu545Arg | p.L545R | protein_coding | tolerated(0.1) | probably_damaging(1) | TCGA-VQ-A8DV-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| MFN1 | insertion | Frame_Shift_Ins | novel | c.394_395insA | p.Ser135GlufsTer6 | p.S135Efs*6 | protein_coding | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| MFN1 | insertion | Frame_Shift_Ins | novel | c.1192_1193insAAACTTGTAACATC | p.Ile398LysfsTer21 | p.I398Kfs*21 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |